Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpLancet Neurology
• journal#1
(no author information available yet)
No abstract text is available yet for this article.
January 3, 2020: Lancet Neurology
#2
Bizhan Aarabi
No abstract text is available yet for this article.
December 20, 2019: Lancet Neurology
#3
Nagy Mekhail, Robert M Levy, Timothy R Deer, Leonardo Kapural, Sean Li, Kasra Amirdelfan, Corey W Hunter, Steven M Rosen, Shrif J Costandi, Steven M Falowski, Abram H Burgher, Jason E Pope, Christopher A Gilmore, Farooq A Qureshi, Peter S Staats, James Scowcroft, Jonathan Carlson, Christopher K Kim, Michael I Yang, Thomas Stauss, Lawrence Poree
BACKGROUND: Spinal cord stimulation has been an established treatment for chronic back and leg pain for more than 50 years; however, outcomes are variable and unpredictable, and objective evidence of the mechanism of action is needed. A novel spinal cord stimulation system provides the first in vivo, real-time, continuous objective measure of spinal cord activation in response to therapy via recorded evoked compound action potentials (ECAPs) in patients during daily use. These ECAPs are also used to optimise programming and deliver closed-loop spinal cord stimulation by adjusting the stimulation current to maintain activation within patients' therapeutic window...
December 20, 2019: Lancet Neurology
#4
Wouter J Schonewille
No abstract text is available yet for this article.
December 9, 2019: Lancet Neurology
#5
Xinfeng Liu, Qiliang Dai, Ruidong Ye, Wenjie Zi, Yuxiu Liu, Huaiming Wang, Wusheng Zhu, Minmin Ma, Qin Yin, Min Li, Xinying Fan, Wen Sun, Yunfei Han, Qiushi Lv, Rui Liu, Dong Yang, Zhonghua Shi, Dequan Zheng, Xiaorong Deng, Yue Wan, Zhen Wang, Yu Geng, Xingyu Chen, Zhiming Zhou, Geng Liao, Ping Jin, Yumin Liu, Xintong Liu, Meng Zhang, Feng Zhou, Hongchao Shi, Yunfeng Zhang, Fuqiang Guo, Congguo Yin, Guozhong Niu, Mei Zhang, Xueli Cai, Qiyi Zhu, Zhonglun Chen, Yingchun Liang, Bing Li, Min Lin, Wei Wang, Haowen Xu, Xinmin Fu, Wenhua Liu, Xiguang Tian, Zili Gong, Haicun Shi, Chuanming Wang, Penghua Lv, Zhonghai Tao, Liangfu Zhu, Shiquan Yang, Wei Hu, Pingzhou Jiang, David S Liebeskind, Vitor M Pereira, Thomas Leung, Bernard Yan, Stephen Davis, Gelin Xu, Raul G Nogueira
BACKGROUND: Previous randomised trials have shown an overwhelming benefit of mechanical thrombectomy for treating patients with stroke caused by large vessel occlusion of the anterior circulation. Whether endovascular treatment is beneficial for vertebrobasilar artery occlusion remains unknown. In this study, we aimed to investigate the safety and efficacy of endovascular treatment of acute strokes due to vertebrobasilar artery occlusion. METHODS: We did a multicentre, randomised, open-label trial, with blinded outcome assessment of thrombectomy in patients presenting within 8 h of vertebrobasilar occlusion at 28 centres in China...
December 9, 2019: Lancet Neurology
#6
C Warren Olanow, Stewart A Factor, Alberto J Espay, Robert A Hauser, Holly A Shill, Stuart Isaacson, Rajesh Pahwa, Mika Leinonen, Parul Bhargava, Ken Sciarappa, Bradford Navia, David Blum
BACKGROUND: Many patients with Parkinson's disease have potentially disabling off episodes that are not predictably responsive to levodopa. In this study, we assessed the safety and efficacy of apomorphine sublingual film as an on-demand therapy for off episodes in patients with Parkinson's disease. METHODS: This randomised, double-blind, placebo-controlled study was done by movement disorder specialists at 32 sites in the USA and one in Canada. Patients with Parkinson's disease who had 2 h or more of off time per day with predictable morning off periods, were responsive to levodopa, and were on stable doses of anti-parkinsonian medication were eligible...
December 6, 2019: Lancet Neurology
#7
Angelo Antonini
No abstract text is available yet for this article.
December 6, 2019: Lancet Neurology
#8
REVIEW
Valery L Feigin, Theo Vos, Emma Nichols, Mayowa O Owolabi, William M Carroll, Martin Dichgans, Günther Deuschl, Priya Parmar, Michael Brainin, Christopher Murray
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. In the past 30 years, the absolute numbers of deaths and people with disabilities owing to neurological diseases have risen substantially, particularly in low-income and middle-income countries, and further increases are expected globally as a result of population growth and ageing. This rise in absolute numbers of people affected suggests that advances in prevention and management of major neurological disorders are not sufficiently effective to counter global demographic changes...
December 5, 2019: Lancet Neurology
#9
Andrea S Winkler
No abstract text is available yet for this article.
December 5, 2019: Lancet Neurology
#10
Eline Wauters, Christine Van Broeckhoven
No abstract text is available yet for this article.
December 3, 2019: Lancet Neurology
#11
Katrina M Moore, Jennifer Nicholas, Murray Grossman, Corey T McMillan, David J Irwin, Lauren Massimo, Vivianna M Van Deerlin, Jason D Warren, Nick C Fox, Martin N Rossor, Simon Mead, Martina Bocchetta, Bradley F Boeve, David S Knopman, Neill R Graff-Radford, Leah K Forsberg, Rosa Rademakers, Zbigniew K Wszolek, John C van Swieten, Lize C Jiskoot, Lieke H Meeter, Elise Gp Dopper, Janne M Papma, Julie S Snowden, Jennifer Saxon, Matthew Jones, Stuart Pickering-Brown, Isabelle Le Ber, Agnès Camuzat, Alexis Brice, Paola Caroppo, Roberta Ghidoni, Michela Pievani, Luisa Benussi, Giuliano Binetti, Bradford C Dickerson, Diane Lucente, Samantha Krivensky, Caroline Graff, Linn Öijerstedt, Marie Fallström, Håkan Thonberg, Nupur Ghoshal, John C Morris, Barbara Borroni, Alberto Benussi, Alessandro Padovani, Daniela Galimberti, Elio Scarpini, Giorgio G Fumagalli, Ian R Mackenzie, Ging-Yuek R Hsiung, Pheth Sengdy, Adam L Boxer, Howie Rosen, Joanne B Taylor, Matthis Synofzik, Carlo Wilke, Patricia Sulzer, John R Hodges, Glenda Halliday, John Kwok, Raquel Sanchez-Valle, Albert Lladó, Sergi Borrego-Ecija, Isabel Santana, Maria Rosário Almeida, Miguel Tábuas-Pereira, Fermin Moreno, Myriam Barandiaran, Begoña Indakoetxea, Johannes Levin, Adrian Danek, James B Rowe, Thomas E Cope, Markus Otto, Sarah Anderl-Straub, Alexandre de Mendonça, Carolina Maruta, Mario Masellis, Sandra E Black, Philippe Couratier, Geraldine Lautrette, Edward D Huey, Sandro Sorbi, Benedetta Nacmias, Robert Laforce, Marie-Pier L Tremblay, Rik Vandenberghe, Philip Van Damme, Emily J Rogalski, Sandra Weintraub, Alexander Gerhard, Chiadi U Onyike, Simon Ducharme, Sokratis G Papageorgiou, Adeline Su Lyn, Amy Brodtmann, Elizabeth Finger, Rita Guerreiro, Jose Bras, Jonathan D Rohrer
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. METHODS: In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers...
December 3, 2019: Lancet Neurology
#12
REVIEW
Elan D Louis, Martin Bares, Julian Benito-Leon, Stanley Fahn, Steven J Frucht, Joseph Jankovic, William G Ondo, Pramod K Pal, Eng-King Tan
In addition to redefining essential tremor (ET), the 2018 consensus statement of the Movement Disorder Society on tremor coined a new term: essential tremor-plus (ET-plus). This term is uncertainly defined as tremor with the characteristics of ET, with additional neurological signs of uncertain clinical significance. If ET-plus had been defined on the basis of a difference in underlying pathology or an appreciable difference in prognosis, it would have a valid, scientific rationale, as does the term Parkinson-plus...
November 22, 2019: Lancet Neurology
#13
Marie Vidailhet
No abstract text is available yet for this article.
November 22, 2019: Lancet Neurology
#14
REVIEW
John F Cryan, Kenneth J O'Riordan, Kiran Sandhu, Veronica Peterson, Timothy G Dinan
Research into the role of the gut microbiome in modulating brain function has rapidly increased over the past 10 years, albeit chiefly in animal models. Increasing clinical and preclinical evidence implicates the microbiome as a possible key susceptibility factor for neurological disorders, including Alzheimer's disease, autism spectrum disorder, multiple sclerosis, Parkinson's disease, and stroke. Cross-sectional clinical studies are bolstering the concept of altered microbial composition contributing to the pathophysiology of such diseases...
November 18, 2019: Lancet Neurology
#15
Stephan Arnold
No abstract text is available yet for this article.
November 13, 2019: Lancet Neurology
#16
Gregory L Krauss, Pavel Klein, Christian Brandt, Sang Kun Lee, Ivan Milanov, Maja Milovanovic, Bernhard J Steinhoff, Marc Kamin
BACKGROUND: More than a third of patients with epilepsy are treatment resistant, and thus new, more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089), an investigational antiepileptic drug, has shown broad-spectrum anticonvulsant activity in preclinical studies and seizure models. We aimed to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal (partial)-onset epilepsy. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled, dose-response study at 107 epilepsy and neurology centres in 16 countries...
November 13, 2019: Lancet Neurology
#17
Linxin Li
No abstract text is available yet for this article.
November 7, 2019: Lancet Neurology
#18
Jie Ding, Kendra L Davis-Plourde, Sanaz Sedaghat, Phillip J Tully, Wanmei Wang, Caroline Phillips, Matthew P Pase, Jayandra J Himali, B Gwen Windham, Michael Griswold, Rebecca Gottesman, Thomas H Mosley, Lon White, Vilmundur Guðnason, Stéphanie Debette, Alexa S Beiser, Sudha Seshadri, M Arfan Ikram, Osorio Meirelles, Christophe Tzourio, Lenore J Launer
BACKGROUND: Dementia is a major health concern for which prevention and treatment strategies remain elusive. Lowering high blood pressure with specific antihypertensive medications (AHMs) could reduce the burden of disease. We investigated whether specific AHM classes reduced the risk for dementia. METHODS: We did a meta-analysis of individual participant data from eligible observational studies published between Jan 1, 1980, and Jan 1, 2019. Cohorts were eligible for inclusion if they prospectively recruited community-dwelling adults; included more than 2000 participants; collected data for dementia events over at least 5 years; had measured blood pressure and verified use of AHMs; included in-person exams, supplemented with additional data, to capture dementia events; and had followed up cases for mortality...
November 6, 2019: Lancet Neurology
#19
Ruth Peters, Craig S Anderson
No abstract text is available yet for this article.
November 6, 2019: Lancet Neurology
#20
Nicolaas I Bohnen, Roger L Albin
No abstract text is available yet for this article.
October 30, 2019: Lancet Neurology
Fetching more papers... 
